<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047836</url>
  </required_header>
  <id_info>
    <org_study_id>19-27571</org_study_id>
    <nct_id>NCT04047836</nct_id>
  </id_info>
  <brief_title>Vaping High vs. Low Nicotine E-Liquid</brief_title>
  <official_title>Vaping High vs. Low Nicotine E-Liquid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of electronic cigarette e-liquid nicotine content in a&#xD;
      randomized, crossover clinical and behavioral pharmacology study of experienced adult&#xD;
      e-cigarette users (N=36). The specific aim is to determine the impact of nicotine content of&#xD;
      e-liquid on nicotine pharmacology, systemic exposure to toxic volatile organic compounds, and&#xD;
      short-term cardiovascular effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a within-subjects, crossover design of advanced electronic cigarette users in which&#xD;
      we will examine nicotine pharmacokinetics, subjective effects, daily nicotine intake and&#xD;
      nicotine titration, short-term cardiovascular effects, and toxicant exposure when&#xD;
      participants are using low vs. high nicotine e-liquids.&#xD;
&#xD;
      Hypothesis 1: E-cigarette users will titrate their intake of nicotine such that they will&#xD;
      inhale fewer aerosol toxicants and suffer less harm to health when using higher vs. lower&#xD;
      nicotine content e-liquids.&#xD;
&#xD;
      Hypothesis 2: Compared to low nicotine, high nicotine e-liquid use will have similar&#xD;
      cardiovascular effects throughout the day (due to compensatory behavioral changes), with&#xD;
      similar effects on heart rate, blood pressure, and catecholamine release.&#xD;
&#xD;
      Hypothesis 3: Exposure to volatile organic compounds (VOCs) will be lower when vaping high&#xD;
      nicotine e-liquids compared to low nicotine e-liquids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover Assignment</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nicotine Exposure</measure>
    <time_frame>Day 1 of each Arm</time_frame>
    <description>Plasma nicotine area under curve (AUC) (ng/ml*h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Effects: Heart Rate</measure>
    <time_frame>Days 1-3 of each Arm</time_frame>
    <description>Participant heart rate will be measured in beats per minute throughout the inpatient stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Effects: Systolic Blood Pressure</measure>
    <time_frame>Day 2 of each Arm</time_frame>
    <description>Participant systolic blood pressure will be taken for 24 hours during ad-lib e-cigarette use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Effects: Diastolic Blood Pressure</measure>
    <time_frame>Day 2 of each Arm</time_frame>
    <description>Participant diastolic blood pressure will be taken for 24 hours during ad-lib e-cigarette use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaping Topography: Puff Number</measure>
    <time_frame>Days 1-3 of each Arm</time_frame>
    <description>Vaping topography measures will be obtained from self-reported participant vaping log during the ad libitum sessions and measured as puffs per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaping Topography: Puff Duration</measure>
    <time_frame>Days 1-3 of each Arm</time_frame>
    <description>Vaping topography measures will be obtained from self-reported participant vaping log during the ad libitum sessions and measured as seconds per puff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaping Topography: Inter-Puff Interval</measure>
    <time_frame>Days 1-3 of each Arm</time_frame>
    <description>Vaping topography measures will be obtained from self-reported participant vaping log during the ad libitum sessions and measured as seconds/minutes between puffs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Low Nicotine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium or High Nicotine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Nicotine E-Liquid</intervention_name>
    <description>Participants will vape e-liquid with nicotine concentration of 3 mg/ml.</description>
    <arm_group_label>Low Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medium or High Nicotine E-Liquid</intervention_name>
    <description>Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.</description>
    <arm_group_label>Medium or High Nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy on the basis of medical history and limited physical examination, as described&#xD;
             below:&#xD;
&#xD;
          -  Heart rate &lt; 105 beats per minute (BPM)*&#xD;
&#xD;
          -  Systolic Blood Pressure &lt; 160 and &gt; 90*&#xD;
&#xD;
          -  Diastolic Blood Pressure &lt; 100 and &gt; 50*&#xD;
&#xD;
             *Considered out of range if both machine and manual readings are above/below these&#xD;
             thresholds.&#xD;
&#xD;
          -  Age: &gt;= 21 years&#xD;
&#xD;
          -  Age: &lt;= 70 years&#xD;
&#xD;
          -  Current regular user of open tank electronic cigarette (EC) (at least 20 times in the&#xD;
             past 30 days) with e-liquid nicotine of 3-6 mg/mL.&#xD;
&#xD;
          -  Non-smoker or non-daily cigarette smokers agreeing to abstain from cigarettes for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Saliva cotinine &gt;50 ng/mL and/or NicAlert=6&#xD;
&#xD;
          -  Carbon monoxide &gt;= 5 ppm or per discretion of Principal Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical&#xD;
&#xD;
          -  Heart disease&#xD;
&#xD;
          -  Seizures&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Thyroid disease (okay if controlled with medication)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Hepatitis B or C or Liver disease&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Kidney disease or urinary retention&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  An ulcer in the past year&#xD;
&#xD;
          -  Active use of an inhaler for Asthma or Chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Psychiatric conditions&#xD;
&#xD;
          -  Current or past schizophrenia, and/or current or past bipolar disorder&#xD;
&#xD;
          -  Major depression, current or within the past year&#xD;
&#xD;
          -  Major personality disorder&#xD;
&#xD;
          -  Participants with current or past minor or moderate depression and/or anxiety&#xD;
             disorders will be reviewed by the PI and considered for inclusion&#xD;
&#xD;
          -  History of psychiatric hospitalizations is not exclusionary, but study participation&#xD;
             will be determined as per PI's approval&#xD;
&#xD;
          -  Drug/Alcohol Dependence&#xD;
&#xD;
          -  Alcohol or illicit drug dependence within the past 12 months with the exception of&#xD;
             those who have recently completed an alcohol/drug treatment program&#xD;
&#xD;
          -  Positive toxicology test for illicit drugs at the screening visit (THC &amp; prescribed&#xD;
             medications okay)&#xD;
&#xD;
          -  Opioid replacement therapy (including methadone, buprenorphine, or other)&#xD;
&#xD;
          -  Psychiatric medications&#xD;
&#xD;
          -  Current regular use of any psychiatric medications with the exception of Selective&#xD;
             Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitors&#xD;
             (SNRIs) and current evaluation by the PI that the participant is otherwise healthy,&#xD;
             stable, and able to participate.&#xD;
&#xD;
          -  Medications&#xD;
&#xD;
          -  Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example:&#xD;
             rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).&#xD;
&#xD;
          -  Use of sympatholytic medications for cardiovascular conditions including hypertension&#xD;
             (Example: beta and alpha-blockers)&#xD;
&#xD;
          -  Concurrent use of nicotine-containing medications&#xD;
&#xD;
          -  Any stimulant medications (example: Adderall) generally given for attention deficit&#xD;
             hyperactivity disorder (ADHD) treatment&#xD;
&#xD;
          -  Other/Misc. Chronic Health Conditions&#xD;
&#xD;
          -  Oral thrush&#xD;
&#xD;
          -  Fainting (within the last 30 days)&#xD;
&#xD;
          -  Other &quot;life threatening illnesses&quot; as per PI's discretion&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pregnancy (self-reported and urine pregnancy test)&#xD;
&#xD;
          -  Breastfeeding (determined by self-report)&#xD;
&#xD;
          -  Concurrent participation in another clinical trial&#xD;
&#xD;
          -  Inability to read and write in English&#xD;
&#xD;
          -  Planning to quit vaping within the next 60 days&#xD;
&#xD;
          -  Concurrent regular use of marijuana (occasional users of these products may be&#xD;
             enrolled if they agree to abstain from their use during the period of the study)&#xD;
&#xD;
          -  Use of other tobacco products, smokeless tobacco, pipes, cigars/cigarillos,&#xD;
             blunts/spliffs (no more than 10 times in the past month and must agree to abstain from&#xD;
             their use during the period of the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Benowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sundos Yassin, BS</last_name>
    <phone>628-206-8955</phone>
    <email>Sundos.Yassin@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sundos Yassin</last_name>
      <phone>628-206-8955</phone>
      <email>sundos.yassin@ucsf.edu</email>
    </contact>
    <contact_backup>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neal L Benowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Neal L Benowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E-Cigarettes</keyword>
  <keyword>Vaping</keyword>
  <keyword>E-Cig Mods</keyword>
  <keyword>E-Liquid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

